Document is current
Any future updates will be listed below
-
Authors
Sogorb-Esteve, Aitana
Swift, Imogen J.
Woollacott, Ione O. C.
Warren, Jason D.
Zetterberg, Henrik
Rohrer, Jonathan D. https://orcid.org/0000-0002-6155-8417
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/M023664/1)
- License Information
-
More Information
Article History
Received: 3 April 2021
Accepted: 24 August 2021
First Online: 3 October 2021
Declarations
:
: The London Queen Square Ethics committee approved the study. The study complies with the Declaration of Helsinki.
: All participants provided written informed consent at enrolment including consent to publication.
: HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JDR has served on medical advisory boards and undertaken consultancy for Alector, Arkuda Therapeutics, Wave Life Sciences, and Prevail Therapeutics. He has also undertaken consultancy for UCB, AC Immune, Astex Pharmaceuticals, Biogen, Takeda and Eisai.
